Clinical Trials Logo

CDD clinical trials

View clinical trials related to CDD.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03861871 Completed - CDD Clinical Trials

Fenfluramine in CDKL5 Deficiency Disorder (CDD)

Start date: October 29, 2019
Phase: Phase 2
Study type: Interventional

This study will be enrolling 10 patients, ages 2-18 years old, with a confirmed genetic/clinical diagnosis of CDKL5 Deficiency Disorder (CDD) in an open label trial of fenfluramine for seizure control. Patients will be titrated over 14 days to a dose of ZX008 0.8 mg/kg/day (maximum dose 30 mg/d).